Edwards Lifesciences Corp Price Target Increased to $79.00 by Analysts at RBC Capital (EW)
Investment analysts at RBC Capital boosted their target price on shares of Edwards Lifesciences Corp (NYSE:EW) from $70.00 to $79.00 in a note issued to investors on Tuesday. The firm currently has a “sector perform” rating on the stock. RBC Capital’s price target suggests a potential downside of 6.95% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Edwards Lifesciences Corp in a research note on Thursday, June 26th. They now have a $89.00 price target on the stock. Separately, analysts at JMP Securities upgraded shares of Edwards Lifesciences Corp from a “market perform” rating to an “outperform” rating in a research note on Wednesday, June 11th. They now have a $97.00 price target on the stock. Finally, analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $87.00 to $90.00 in a research note on Thursday, May 22nd. They now have a “buy” rating on the stock. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $84.35.
Shares of Edwards Lifesciences Corp (NYSE:EW) traded down 0.16% on Tuesday, hitting $84.76. 369,383 shares of the company’s stock traded hands. Edwards Lifesciences Corp has a one year low of $60.62 and a one year high of $88.41. The stock has a 50-day moving average of $84.96 and a 200-day moving average of $77.29. The company has a market cap of $8.942 billion and a price-to-earnings ratio of 30.84.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.